In This Article:
Over the last 7 days, the United States market has experienced a 1.7% drop, yet it remains up by 12% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in an evolving market landscape.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 26.19% | 37.78% | ★★★★★★ |
| Alkami Technology | 21.98% | 85.17% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| AVITA Medical | 27.78% | 55.33% | ★★★★★★ |
| Bitdeer Technologies Group | 44.71% | 127.60% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.90% | 58.64% | ★★★★★★ |
| Blueprint Medicines | 22.38% | 55.75% | ★★★★★★ |
| Alvotech | 31.17% | 100.18% | ★★★★★★ |
| Lumentum Holdings | 21.24% | 119.37% | ★★★★★★ |
Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Ardelyx
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines for unmet medical needs both in the United States and internationally, with a market cap of $1.26 billion.
Operations: Ardelyx generates revenue primarily through the development and commercialization of biopharmaceutical products, totaling $333.62 million.
Ardelyx has recently shown promising developments, notably with the approval of its New Drug Application in China for tenapanor, which is expected to generate up to $100 million in milestone payments plus royalties. This approval reflects Ardelyx's strategic expansion into international markets, potentially boosting its revenue streams significantly. Furthermore, the company's recent earnings report indicates a robust recovery with a year-over-year revenue increase from $124.46 million to $333.62 million and a shift from a net loss to net income in Q4 2024. These financial improvements, coupled with an anticipated annual earnings growth rate of 54%, position Ardelyx for potential profitability and sustained growth in the biotech sector.
-
Navigate through the intricacies of Ardelyx with our comprehensive health report here.
-
Explore historical data to track Ardelyx's performance over time in our Past section.
Bentley Systems
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Bentley Systems, Incorporated offers infrastructure engineering software solutions across various global regions and has a market cap of approximately $13.59 billion.
Operations: The company generates revenue primarily from computer software and related services, amounting to approximately $1.35 billion. Its operations span several global regions, focusing on infrastructure engineering solutions.